Principal Investigator/Program Director (Last, First, Middle): Bredel, Markus, M.D., Ph.D.
BIOGRAPHICAL SKETCH
Provide the...
Principal Investigator/Program Director (Last, First, Middle): Bredel, Markus, M.D., Ph.D.
1997-2001 Scholarship, German N...
Principal Investigator/Program Director (Last, First, Middle): Bredel, Markus, M.D., Ph.D.
Bredel, M., Jacoby, E.: Chemoge...
Principal Investigator/Program Director (Last, First, Middle): Bredel, Markus, M.D., Ph.D.
C. Research Support.
Pending Re...
Upcoming SlideShare
Loading in...5
×

Markus Bredel, MD, PhD

624

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
624
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Markus Bredel, MD, PhD

  1. 1. Principal Investigator/Program Director (Last, First, Middle): Bredel, Markus, M.D., Ph.D. BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME Markus Bredel, M.D., Ph.D. POSITION TITLE Director, Northwestern Brain Tumor Institute Basic Science Program, Northwestern UniversityeRA COMMONS USER NAME: MBREDEL EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) INSTITUTION AND LOCATION DEGREE (if applicable) YEAR(s) FIELD OF STUDY University of Vienna, Vienna, Austria M.D. 2000 Brain Tumor Biology Free University of Berlin, Berlin, Germany Ph.D. 2001 Exp. Neuro-oncology Stanford University, Stanford, CA Fellow 2003-2005 Exp. Neuro-oncology A. Positions and Honors. Employment/Experience 12/31/2006- Director, Northwestern Brain Tumor Institute Basic Science Program, Feinberg School of Medicine, Northwestern University, Chicago, IL 12/31/2006- Asst. Professor, Department of Neurological Surgery, Robert H. Lurie Comprehensive Cancer Center, Center for Genetic Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 12/31/2006- Adjunct Asst. Professor, Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 2005-2006 Vis. Asst. Professor, Department of Neurosurgery, Center for Clinical Sciences Research, Stanford University School of Medicine, Stanford, CA 2003-present Asst. Professor of Exp. Neuro-oncology (on leave), Department of General Neurosurgery, Neurocenter, University of Freiburg, Freiburg, Germany 2003-05 Research Fellow, Division of Oncology, Center for Clinical Sciences Research, Stanford University School of Medicine, Stanford, CA (Mentor: Branimir I. Sikic) 2001-03 Resident in Neurosurgery, Department of General Neurosurgery, Neurocenter, University of Freiburg, Freiburg, Germany (Mentor: Josef Zentner) 1998-2001 Researcher in neuro-oncology, Institute of Neurology, Department of Neuropathology, University of Vienna, Vienna, Austria (Mentor: Herbert Budka) 1996.97 Vis. Research Fellow in experimental neuro-oncology, University of Pittsburgh Cancer Institute Brain Tumor Center and Department of Neurosurgery, Pittsburgh, PA (Mentor: Ian F. Pollack) Honors, Awards, and Scholarships 2006 Merit Award, American Society of Clinical Oncology (ASCO) 2006 German Pfizer Research Award for Medicine, University of Freiburg 2005 Finalist, Paul Ehrlich and Ludwig Darmstaedter-Young Investigator Award 2006, Paul-Ehrlich-Society 2003-05 Scholar, Emmy-Noether Excellence Program, German Research Foundation 2003 Venia legendi (Experimental Neuro-oncology), University of Freiburg, Freiburg, Germany 2003 Preuss Research Award 2003, best translational neuro-oncology research, American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS), Section on Tumors 2002 Lifeline Column, The Lancet 2002 Benjamin Franklin Award, best doctoral thesis 2001, Faculty of Medicine of the Free University of Berlin 2001 M.D./Ph.D., summa cum laude, Free University of Berlin, Berlin, Germany 2000 M.D., excellent, University of Vienna, Vienna, Austria 1999-2000 Hölderlin Foreign Exchange Scholarship, Alfried Krupp von Bohlen and Halbach-Foundation and German National Merit Foundation PHS 398/2590 (Rev. 09/04) Page 1 of 4 Biographical Sketch Format Page
  2. 2. Principal Investigator/Program Director (Last, First, Middle): Bredel, Markus, M.D., Ph.D. 1997-2001 Scholarship, German National Merit Foundation 1997 Rhone-Poulenc-Rorer Young Investigator Award 1997 of the American Association for Cancer Research (AACR) Memberships in Professional Associations 2005-present The Society for Neuro-oncology (SNO) 2005-present European Association for Neuro-Oncology (EANO) 2005-present European Association for Cancer Research (EACR) 2004-present American Society of Clinical Oncology (ASCO) 2004-present American Association for the Advancement of Science (AAAS) 2002-present German Cancer Society/Neuro-oncology Working Group (NOA) 2002-present Associate American Association for Cancer Research (AACR) 2001-present German Medical Association Extracurricular Activities 2006-present Chair, Central Nervous System Tumors Subcommittee, Scientific Program Committee, American Society of Clinical Oncology (ASCO) 2006-present Translational Research Chair, Central Nervous System Tumors Subcommittee, American Society of Clinical Oncology (ASCO) 2006-present Member, Best of ASCO Program Committee, American Society of Clinical Oncology (ASCO) 2006-present Member, Core Reviewer Panel, Italian Association for Cancer Research (AIRC) 2006-present Education Committee Member, Central Nervous System Tumors Track, American Society of Clinical Oncology (ASCO) 2005-06 Scientific Program Committee Member, Central Nervous System Tumors Subcommittee, American Society of Clinical Oncology (ASCO) 2005-present Member, Reviewer Panel, Arizona Biomedical Research Commission 2004-present Scientific Reviewer, Austrian National Bank, Anniversary Fund 2003-present Editorial Board, The Lancet Oncology 2001-present Scientific Reviewer, Dutch Cancer Society 2001-present Ad hoc Reviewer: Nature Medicine, The Lancet Oncology, Molecular Biology of the Cell, Cell Death and Differentiation, FEBS Letters, Journal of Clinical Pathology, Current Cancer Drug Targets, British Journal of Cancer, etc. B. Peer-reviewed publications (in chronological order). Bagachi, A., Papazoglu, C., Capurso, D., Wu, Y., Brodt, M., Bredel, M., Vogel, H., Mills, A.: CHD5 is a Novel Tumor Suppressor at Human 1p36. Cell 128: 459-475, 2007. Bredel, M., Bredel, C., Juric, D., Duran, G., Yu, R., Harsh IV, G.R., Vogel, H., Recht, L.D., Scheck, A.C., Sikic, B.I.: Tumor Necrosis Factor-α–Induced Protein 3 As a Putative Regulator of Nuclear Factor-κB–Mediated Resistance to O6 -Alkylating Agents in Human Glioblastomas. J. Clin. Oncol. 24: 274-287, 2006. Bredel, M., Bredel, C., Juric, D., Harsh IV, G.R., Vogel, H., Recht, L.D., Sikic, B.I.: Functional Network Analysis Reveals Extended Gliomagenesis Pathway Maps and Three Novel MYC-Interacting Genes in Human Gliomas. Cancer Res. 65: 8679-8689, 2005. Bredel, M., Bredel, C., Juric, D., Harsh IV, G.R., Vogel, H., Recht, L.D., Sikic, B.I.: High-Resolution Genome-Wide Mapping of Genetic Alterations in Human Glial Brain Tumors. Cancer Res. 65: 4088-4096, 2005. Bredel, M., Bredel, C., Juric, D., Kim, Y., Vogel, H., Harsh IV, G.R., Recht, L.D., Pollack, J.R., Sikic, B.I.: Amplification of Whole Tumor Genomes and Gene-by-Gene Mapping of Genomic Aberrations from Limited Sources of Fresh- Frozen and Paraffin-Embedded DNA. J. Mol. Diagn. 7: 171-182, 2005. Bredel, C., Lassmann, S., Pollack, I.F., Knoth, R., Hamilton, R.L., Werner, M., Bredel, M.: DNA Topoisomerase IIα and Her-2/neu Gene Dosages in Pediatric Malignant Gliomas. Int. J. Oncol. 26: 1187-1192, 2005. PHS 398/2590 (Rev. 09/04) Page 2 of 4 Biographical Sketch Format Page
  3. 3. Principal Investigator/Program Director (Last, First, Middle): Bredel, Markus, M.D., Ph.D. Bredel, M., Jacoby, E.: Chemogenomics: An Emerging Strategy for Rapid Target and Drug Discovery. Nat. Rev. Genet. 4: 262-275, 2004. Bredel, M., Bredel, C., Sikic, B.I.: Genomics-based Hypothesis Generation: A Novel Approach to Unravelling Drug Resistance in Brain Tumors? Lancet Oncol. 5: 89-100, 2004. Birner, P., Fischer, I., Gatterbauer, B., Marosi, C., Ambros, I.M., Bredel, M., Oberhuber, G., Rössler, K., Budka, H., Harris, A., Hainfellner, J.: Vascular Patterns in Glioblastoma Influence Clinical Outcome and Associate with Variable Expression of Angiogenic Proteins: Evidence for Distinct Angiogenic Subtypes. Brain Pathol. 13: 133-143, 2003. Bredel, M.: Predicting Outcome and Tailoring Treatment in High-Grade Gliomas. Lancet Oncol. 4: 269-270, 2003. Bredel, M., Gatterbauer, B., Birner, P., Haberler, C., Ströbel, T., Budka, H., Rössler, K., Hainfellner, J.A.: Expression of DNA Topoisomerase IIα in Oligodendroglioma. Anticancer Res. 22: 1301-1304, 2002. Bredel, M., Zentner, J.: Brain Tumor Drug Resistance: The Bare Essentials. Lancet Oncol. 3: 397-406, 2002. Bredel, M., Pollack, I.F., Hamilton, R.L., Birner, P., Hainfellner, J.A., Zentner, J.: Topoisomerase IIα Predicts Progression-Free and Overall Survival in Pediatric Malignant Non-Brainstem Gliomas. Int. J. Cancer 99: 817-820, 2002. Bredel, M., Piribauer, M., Marosi, C., Birner, P., Gatterbauer, B., Fischer, I., Ströbel, T., Rössler, K., Budka, H., Hainfellner, J.A.: High Expression of DNA Topoisomerase IIα and Ki-67 Antigen is Associated with Prolonged Survival in Glioblastoma Patients. Eur. J. Cancer 38: 1343-1347, 2002. Bredel, M., Slavc, I., Birner, P., Czech, T., Haberler, C., Ströbel, T., Wolfsberger, S., Budka, H., Hainfellner, J.A.: DNA Topoisomerase IIα Expression in Optic Pathway Gliomas of Childhood. Eur. J. Cancer 38: 393-400, 2002. Bredel, M.: Anticancer Drug Resistance in Primary Human Brain Tumors. Brain Res. Rev. 35: 161-204, 2001. Pollack, I.F., Bredel, M., Erff, M., Hamilton, A.D., Sebti, S.M.: Inhibition of Ras and Related Guanosine Triphosphate- Dependent Proteins as a Therapeutic Strategy for Blocking Malignant Glioma Growth: II – Preclinical Studies in a Nude Mouse Model. Neurosurgery 45: 1208-1215, 1999. Bredel, M., Pollack, I.F., Hamilton, R.L., James, C.D.: Epidermal Growth Factor Receptor Expression in High-Grade Non-Brainstem Gliomas of Childhood. Clin. Cancer Res. 5: 1786-1792, 1999. Bredel, M., Pollack, I.F., Freund, J.M., Rusnak, J., Lazo, J.S.: Protein Kinase C Inhibition by UCN-01 Induces Apoptosis in Human Glioma Cells in a Time-Dependent Fashion. J. Neurooncol. 41: 9-20, 1999. Bredel, M., Pollack, I.F.: The p21-Ras Signal Transduction Pathway and Growth Regulation in Human High-Grade Gliomas. Brain Res. Rev. 29: 232-249, 1999. Pollack, I.F., Bredel, M., Erff, M.: Application of Signal Tranduction Inhibition as a Therapeutic Strategy for Central Nervous System Tumors. Pediatr. Neurosurg. 29: 228-244, 1998. Bredel, M., Pollack, I.F., Freund, J.M., Hamilton, A.D., Sebti, S.M.: Inhibition of Ras and Related G-Proteins as a Therapeutic Strategy for Blocking Malignant Glioma Growth. Neurosurgery 43: 124-132, 1998. Bredel, M., Pollack, I.F., Campbell, J.W., Hamilton, R.L.: Basic Fibroblast Growth Factor Expression as a Predictor of Prognosis in Pediatric High-Grade Gliomas. Clin. Cancer Res. 3: 2157-2164, 1997. Bredel, M., Pollack, I.F.: The Role of Protein Kinase C (PKC) in the Evolution and Proliferation of Malignant Gliomas, and the Application of PKC Inhibition as a Novel Approach to Anti-Glioma Therapy. Acta Neurochir. 139: 1000- 1013, 1997. Juric, D., Bredel, C., Sikic, B.I., Bredel, M.: Integrated cDNA Microarray-based Gene Dosage and Gene Expression Analysis in Human Brain Tumors. Methods Mol. Biol., in press, 2006. Bredel, M., et al.: Nonrandom Selection of a Cooperative Genetic Landscape during Brain Tumor Evolution. Submitted, 2006. Bredel, M., et al.: Nuclear Factor-κB Inhibitor α Predicts Outcome of Human High-Grade Gliomas. In progress, 2006. Bredel, M., et al.: An Interwoven Network of Endogenous Modulators of Canonical Nuclear Factor-κB Pathway Activation Predicts Outcome of Human High-Grade Gliomas in a Cooperative Fashion. In progress, 2006. Bredel, M., et al.: Genetic Alterations Involving Chromosomal Territories 19 and 20 Denote Distinct Molecular Signatures of Glioblastoma Multiforme. In progress, 2006. PHS 398/2590 (Rev. 09/04) Page 3 of 4 Biographical Sketch Format Page
  4. 4. Principal Investigator/Program Director (Last, First, Middle): Bredel, Markus, M.D., Ph.D. C. Research Support. Pending Research Support 1R01CA131516-01 Bredel (PI) 12/01/07 – 11/30/12 Stanford University School of Medicine “Endogenous Modulators of Nuclear Factor–κB and High-Grade Glioma Outcome” This proposal seeks to explore the individual and cooperative role of endogenous modulators of canonical NF−κB activation in the response of high-grade gliomas to O6 -alkylating chemotherapeutics such as temozolomide. Role: PI Additional pending research support from The Goldhirsh Foundation, the National Brain Tumor Foundation, and the James S. McDonnell Foundation. Completed Research Support Bredel (PI) 12/01/05 – 12/31/06 Stanford University School of Medicine “Molecular Genetics of Human Gliomas” This project has utilized microarray methodology and gene dosage/expression integration, network, and interactome modeling algorithms to provide mechanistic explanation for the nonrandom coincidence of distinct chromosomal alterations in human gliomas. Role: PI BR 2252/1-1 Bredel (PI) 03/01/03 – 02/28/05 German Research Foundation / Emmy-Noether-Program “Chemoresistance in Glioblastoma Multiforme: Towards Integrated Pharmacogenomic Analysis of Chemotherapeutically Perturbed In Vitro and In Vivo Systems Applying the Hypothesis-Generation-Paradigm” This project has used an integrated resistance model and genomics tools to globally explore molecular factors and cellular pathways mediating resistance to O6-alkylating agents in glioblastoma cells and has identified the tumor necrosis factor-α–induced protein 3 (TNFAIP3) gene as a factor associated with glioblastoma cell resistance. Role: PI PHS 398/2590 (Rev. 09/04) Page 4 of 4 Biographical Sketch Format Page

×